NCT00211159 · COMPLETED
OmegAD (Omega-3 and Alzheimer's Disease)
This trial tested whether a daily omega-3 fish oil supplement, rich in DHA, could slow memory and thinking decline in people who already have Alzheimer's. Researchers tracked cognitive scores over time. The phase is listed as not applicable, which usually means it was not a standard drug-development trial. It does not show the supplement works.
Eligibility criteria
Inclusion Criteria: Alzheimer's disease with MMSE 15-30, living in own homes, treated with stable dose of acetylcholine esterase inhibitor for >3 months and remaining on that treatment for the study period Exclusion Criteria: Already treated with omega-3 fatty acids, NSAIDs, warfarin, being an alcohol abuser, suffering from serious concomitant disease or not having a caregiver
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2017-07-31